Max Robotics — Global Service Robot Directory + US Certification

About

Mike Notohamiprodjo is a leading researcher in prostate cancer diagnostics, specializing in advanced imaging and biopsy techniques. His work centers on improving the accuracy of prostate cancer detection through multiparametric magnetic resonance imaging (mpMRI) and robot-assisted transperineal fusion biopsy. Notohamiprodjo’s major contributions include pioneering the evaluation of targeted versus systematic biopsy approaches, demonstrating that robot-assisted targeted biopsy significantly enhances cancer detection rates, particularly in repeat biopsy settings. His 2017 study on this topic, with 33 citations, is a cornerstone in the field. He also advanced quantitative MRI methods, such as T2 mapping, to differentiate prostate cancer from benign conditions like chronic prostatitis, a critical step in reducing unnecessary biopsies. His 2022 work on T2 mapping (22 citations) highlights his role in refining non-invasive diagnostic tools. Notohamiprodjo’s research has directly influenced clinical protocols, reducing false positives and improving patient outcomes. His innovative use of robotics and imaging integration marks him as a key figure in precision urology, with his findings widely adopted in prostate cancer management guidelines.